Individualized Hormone Replacement Therapy Versus
Ovarian Transplantation

BM Petrikovsky; EV Zharov; M Cohen

Editorial

Individualized Hormone Replacement Therapy Versus Ovarian Transplantation

BM Petrikovsky¹*, EV Zharov² and M Cohen³

¹Chairman of Obstetrics and Gynecology, Nassau University Medical Center, USA

²Russian Federation Academy of Science, Russia

³Private practice, Hartford, CT, USA

Corresponding Author

Received Date: February 09, 2019; Published Date: February 12, 2019

Abstract

Numerous studies conclude that risks and benefits of hormonal replacement therapy (HRT) are dose-dependent [1]. The pharmaceutical industry attempted to partially resolve the issue of individualization of HRT by manufacturing at least six different types of Minivelle patches (0.024mg, 0.0375mg, 0.05mg, 0.075mg, and 0.1mg). The choices offered by the pharmaceuticals are useful but fail to caliber dose based on the needs of the individual patient.

Article Details

Citation

BM Petrikovsky, EV Zharov, M Cohen. Individualized Hormone Replacement Therapy Versus Ovarian Transplantation. W J Gynecol Women’s Health. 1(5): 2019. WJGWH.MS.ID.000525.